(4R)-N-[(1S)-1-Methyl-2-nitroxyethyl]-2-oxothiazolidin-4-yl-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-N-[(1S)-1-Methyl-2-nitroxyethyl]-2-oxothiazolidin-4-yl-carboxamide
• 英文别名: [(2S)-2-[[(4R)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]propyl] nitrate
• 化学式: C₇H₁₁N₃O₅S
• 分子量: 249.247
• InChiKey: FKXIFERJNLWUMJ-WHFBIAKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  丙半胱氨酸 、 [(2S)-2-aminopropyl] nitrate 在 焦碳酸二乙酯 作用下， 生成 (4R)-N-[(1S)-1-Methyl-2-nitroxyethyl]-2-oxothiazolidin-4-yl-carboxamide
  参考文献：
  名称：

  Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties

  摘要：

  To develop an orally active, long-acting nitrate that does not induce tolerance, nitroxyalkyl compounds were prepared and their activities evaluated by the use of carotid collaterals in anesthetized dogs. A compound having a favorable pharmacological profile, that is, long-lasting collateral vasodilatation and little hypotension, and lack of nitrate tolerance, was chosen for further evaluation. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00199-9

文献信息

• Method for treating or preventing ulcerative diseases by administering
  申请人：Sankyo Company, Limited

  公开号：US05891898A1

  公开（公告）日：1999-04-06

  A method for the treatment or prevention of an ulcerative disease comprising administering to a patient an effective amount of an active compound in admixture with a pharmacologically acceptable carrier or diluent, wherein said active compound is a thia-or oxazolidinone compound of the following formula or a pharmacologically acceptable salt thereof: ##STR1## wherein W is sulfur or oxygen and X is --N(R.sup.3)--, or X is sulfur or oxygen and W is --N(R.sup.3)--; R.sup.3 is hydrogen, C.sub.1 -C.sub.6 alkyl or aralkyl; R.sup.4 and R.sup.5 are the same or different and each is hydrogen, C.sub.1 -C.sub.6 alkyl,aralkyl, aryl, 5- or 6-membered aromatic heterocyclic; R.sup.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or aralkyl; and A is C.sub.2 -C.sub.6 alkylene.

  一种治疗或预防溃疡性疾病的方法，包括向患者施用与药理学上可接受的载体或稀释剂混合的有效量的活性化合物，其中所述活性化合物是以下公式或其药理学上可接受的盐的硫或氧的噻唑烷或噁唑烷化合物： ##STR1## 其中W是硫或氧，X是--N（R3）--，或X是硫或氧，W是--N（R3）--；R3是氢，C1-C6烷基或芳基烷基；R4和R5相同或不同，每个是氢，C1-C6烷基，芳基烷基，芳基，5-或6-成员的芳香杂环；R6是氢，C1-C6烷基或芳基烷基；A是C2-C6烷基。
• Optically active thiazolidinone derivative
  申请人：Sankyo Company, Limited

  公开号：US05925658A1

  公开（公告）日：1999-07-20

  An optically active thiazolidinone derivative having the general formula: ##STR1## wherein: R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.4 alkyl group, a phenyl group, a substituted phenyl group (said substituent represents C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or halogen), a phenyl-C.sub.1 -C.sub.2 alkyl group or a substituted phenyl-C.sub.3 -C.sub.2 alkyl group (the substituent of said phenyl represents C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or halogen); R.sup.2 represents a C.sub.1 -C.sub.6 alkyl group; and n represents 1 or 2!. Effect The optically active thiazolidinone derivative of the present invention has excellent anti-angina pectoris action and is useful as a preventive agent or a therapeutic agent for angina pectoris.

  具有以下通式的旋光异噻唑烷衍生物：##STR1## 其中：R.sup.1代表氢原子、C.sub.1-C.sub.4烷基、苯基、取代苯基（所述取代基代表C.sub.1-C.sub.4烷基、C.sub.1-C.sub.4烷氧基或卤素）、苯-C.sub.1-C.sub.2烷基或取代苯-C.sub.3-C.sub.2烷基（所述苯基的取代基代表C.sub.1-C.sub.4烷基、C.sub.1-C.sub.4烷氧基或卤素）；R.sup.2代表C.sub.1-C.sub.6烷基；n代表1或2！。 作用 本发明的旋光异噻唑烷衍生物具有优异的抗心绞痛作用，并可用作心绞痛的预防剂或治疗剂。
• Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties
  作者：Sadao Ishihara、Fujio Saito、Yasuo Ohhata、Marie Kanai、Hiroshi Mizuno、Michio Fujisawa、Ryosuke Yorikane、Hiroyuki Koike

  DOI：10.1016/s0960-894x(03)00199-9

  日期：2003.5

  To develop an orally active, long-acting nitrate that does not induce tolerance, nitroxyalkyl compounds were prepared and their activities evaluated by the use of carotid collaterals in anesthetized dogs. A compound having a favorable pharmacological profile, that is, long-lasting collateral vasodilatation and little hypotension, and lack of nitrate tolerance, was chosen for further evaluation. (C) 2003 Elsevier Science Ltd. All rights reserved.